Predicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy
Bioengineering & Translational Medicine · 2024-01 · 9 (1)
DOI: 10.1002/btm2.10595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 31.08.2023. Verfasst von Saman Ghazvini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering Iowa State University Ames Iowa USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NICHD NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Preeclampsia is a life‐threatening pregnancy disorder. Current clinical assays cannot predict the onset of preeclampsia until the late 2nd trimester, which often leads to poor maternal and neonatal outcomes. Here we show that Raman spectroscopy combined with machine learning in pregnant patient plasma enables rapid, highly sensitive maternal metabolome screening that predicts preeclampsia as early as the 1st trimester with >82% accuracy. We identified 12, 15 and 17 statistically significant metabolites in the 1st, 2nd and 3rd trimesters, respectively. Metabolic pathway analysis shows multiple pathways corresponding to amino acids, fatty acids, retinol, and sugars are enriched in the preeclamptic cohort relative to a healthy pregnancy. Leveraging Pearson's correlation analysis, we show for the first time with Raman Spectroscopy that metabolites are associated with several clinical factors, including patients' body mass index, gestational age at delivery, history of preeclampsia, and severity of preeclampsia. We also show that protein quantification alone of proinflammatory cytokines and clinically relevant angiogenic markers are inadequate in identifying at‐risk patients. Our findings demonstrate that Raman spectroscopy is a powerful tool that may complement current clinical assays in early diagnosis and in the prognosis of the severity of preeclampsia to ultimately enable comprehensive prenatal care for all patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical and Biological Engineering Iowa State University Ames Iowa USA.
- Nanovaccine Institute Iowa State University Ames Iowa USA.
- Department of Chemistry and Biochemistry National Chung Cheng University Chiayi Taiwan.
- Department of Mechanical Engineering Iowa state University Ames Iowa USA.
- Department of Obstetrics and Gynecology, Carver College of Medicine University of Iowa, Hospitals & Clinics Iowa City Iowa USA.
ORCID-Profile: Rizia Bardhan
Förderung
- NIBIB NIH HHS
- NICHD NIH HHS
- NCATS NIH HHS
- American Heart Association
- Ministry of Science and Technology, Taiwan
- National Institutes of Health
Zitieren
APA
Ghazvini, S., Uthaman, S., Synan, L., Lin, E. C., Sarkar, S., Santillan, M. K., Santillan, D. A., & Bardhan, R. (2024). Predicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy. Bioengineering & Translational Medicine, 9(1). https://doi.org/10.1002/btm2.10595
Vancouver
Ghazvini S, Uthaman S, Synan L, Lin EC, Sarkar S, Santillan MK, et al. Predicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy. Bioengineering & Translational Medicine. 2024;9(1). doi:10.1002/btm2.10595
BibTeX
@article{Ghazvini2024,
author = {Ghazvini, Saman and Uthaman, Saji and Synan, Lilly and Lin, Eugene C and Sarkar, Soumik and Santillan, Mark K and Santillan, Donna A and Bardhan, Rizia},
title = {Predicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy},
journal = {Bioengineering & Translational Medicine},
year = {2024},
volume = {9},
number = {1},
doi = {10.1002/btm2.10595}
}
EUVIMED